PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Single Intranasal Mebufotenin Dose Cuts Depression Scores in Treatment-Resistant Depression

mebufotenin5-MeO-DMTBPL-003intranasal psychedelic5-HT2A agonist5-HT1A agonisttreatment-resistant depressionmajor depressive disorderrandomized controlled trialphase 2bMADRSpsychopharmacology Psychiatry / Psychopharmacology

Background Information

Intranasal mebufotenin offers fast relief for treatment-resistant depression.

Treatment-resistant depression poses a significant clinical challenge, and intranasal psychedelics may offer new treatment options with less intensive monitoring requirements. Intranasal mebufotenin benzoate significantly reduced Montgomery-Asberg Depression Rating Scale scores at both 8 mg and 12 mg doses compared to 0.3 mg, with rapid discharge readiness. This phase 2b study shows promise for intranasal mebufotenin as a well-tolerated option for treatment-resistant depression, although further validation in larger trials is needed. Intranasal mebufotenin offers rapid and durable symptom relief in treatment-resistant depression with shorter monitoring times.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Feifel D, Seynaeve M, Cubala WJ, Dunbar F, Gründer G, Dueñas Herrero RM, Hindocha C, Liknaitzky P, McGuigan SM, Mehta S, Pierce M, Repantis D, Roberts C, Wiegand F, Conley R

Citation: Feifel D, Seynaeve M, Cubala WJ, et al. Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA. 2026. doi:10.1001/jama.2026.18380

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.